AI Summary & Key Takeaways
AI InsightSeven 77.8% of 9 cirrhotic patients completed the planned treatment and sustained virological response was achieved in 5 55.6 patients. 12 85.7% of 14 non-cirrhotic patients completed the planned treatment and sustained virological response was achieved in 11 78.5% patients.Treatment was discontinued in 4 17.4% patients due to various side effects.Conclusion: Taking into consideration that novel interferon free treatment regimens are not available in our country yet, triple combination with Pegylated interferon+ribavirin and protease inhibitor is still a treatment option for chronic hepatitis C in selected cases
📌 3 Key Takeaways
Abstract
Objective: Pegylated interferon+ribavirin dual combination had been the standard treatment for chronic hepatitis C for years.Recently protease inhibitors were added to this combination.In this manuscript, we aimed to review the data of the patients to whom Pegylated interferon+ribavirin+protease inhibitor containing triple therapy regimen were given in our clinic.Material and Method: This was a retrospective study and 23 chronic hepatitis C patients treated with triple therapy regimen in Necmettin Erbakan University, Meram Faculty of Medicine, Department of Gastroenterology, between December 2012 and December 2015 were included.Results: There were 18 78.3% male and 5 21.7% female patients and median age was 58 years range 42-70 years . 16 69.6% patients achieved sustained virological response. Thirteen 72.2% of 18 patients on telaprevir regimen and 3 60% of 5 patients on boceprevir regimen achieved sustained virological response.When virological response in the prior pegylated interferon+ribavirin treatment was taken into consideration;10 90.1% of 11 patients with relapse,3 patients 100% with partial response and 2 50% of 4 non-responders were found to achieve sustained virological response. Seven 77.8% of 9 cirrhotic patients completed the planned treatment and sustained virological response was achieved in 5 55.6 patients. 12 85.7% of 14 non-cirrhotic patients completed the planned treatment and sustained virological response was achieved in 11 78.5% patients.Treatment was discontinued in 4 17.4% patients due to various side effects.Conclusion: Taking into consideration that novel interferon free treatment regimens are not available in our country yet, triple combination with Pegylated interferon+ribavirin and protease inhibitor is still a treatment option for chronic hepatitis C in selected cases
Özet
Amaç: Pegile interferon+ribavirin kombinasyonu uzun yıllar kronik hepatit C tedavisinde standart tedavi olmuştur. Son yıllarda proteaz inhibitörleri bu kombinasyona ilave edilmiş ve daha yüksek kalıcı virolojik yanıt oranları elde edilebilmiştir. Biz bu çalışmada kliniğimizde takip edilen ve PEG-İFN+ribavirin+proteaz inhibitörü içeren üçlü tedavi alan hastalarımızın verilerini retrospektif olarak değerlendirmeyi amaçladık.Gereç ve Yöntem: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Gastroenteroloji Kliniğine Aralık 2012-Aralık 2015 tarihleri arasında başvuran ve proteaz inhibitörü içeren 3’lü tedavi verilen 23 kronik HCV hastasının verileri retrospektif olarak incelenmiştir.Bulgular: Hastaların 18’i %78,3 kadın ve 5’i %21,7 erkek ve median yaşları 58 yıl Aralık 42-70 yıl idi. Toplam 16 hastada %69,6 kalıcı virolojik yanıt elde edilmişti. Telaprevir kullanan 18 hastanın 13’ünde %72,2 ve boseprevir kullanan 5 hastanın 3’ünde %60 kalıcı virolojik yanıt elde edildi. Daha önce PEG IFN+ribavirin ikili tedavisi alıp nüks olan 11 hastanın 10’unda %90,1 , kısmi yanıt veren 3 hastanın tamamında ve ilk tedavide primer yanıtsız olan 4 hastanın 2’sinde %50 kalıcı virolojik yanıt elde edildi. Sirotik olan 9 hastanın 7’si %77,8 planlanan tedavi süresini tamamladı, 5 hastada %55,6 kalıcı virolojik yanıt elde edildi. Sirozu olmayan 14 hastanın 12’si %85,7 tedaviyi tamamlarken, bu hastaların 11’inde %78,5 kalıcı virolojik yanıt elde edildi. 4 hastada %17,4 çeşitli yan etkiler nedeniyle tedavi süresi tamamlanamadı.Sonuç: İnterferonsuz tedavi rejimlerinin ülkemizde henüz rutin kullanıma girmediği göz önüne alınırsa, seçilmiş vakalarda PEG IFN, ribavirin ve bir proteaz inhibitörü içeren üçlü tedavilerin hala bir seçenek olabileceği kanaatindeyiz